Skip to main content
Fig. 7 | Journal of Experimental & Clinical Cancer Research

Fig. 7

From: RORγt agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers

Fig. 7

Type17 T cell activates the Ccr6-pAKT-STAT3-Cxcl10 axis in the MoDC. a Statistical results on the migrated Mo-DCs in the bottom chamber. Data shown is the mean ± SD from a representative experiment. N = 3, * P < 0.05; *** P < 0.001 and **** P < 0.0001 by Student’s t-test. b mRNA level of Ccl20 in Th17 cells with or without LYC-55716 or 8-074 by qPCR, respectively (*P < 0.05, ****P < 0.0001). c The mRNA expression level of Ccr6 in the DC cells treated with the Th17 supernatant was detected by qPCR compared with the medium only (*P < 0.05). d The ratio of pAKT+ DC cells and pSTAT3+ DC cells to the CD45+ cells in the MoDC treated with the Th17 supernatant was measured by flow cytometry compared with the MoDC treated with the medium only (**P < 0.01, ****P < 0.0001). e The expression level of Cxcl10 mRNA in the MoDC treated with the Th17 supernatant was detected by qPCR compared with the MoDC treated with the medium only (*P < 0.05). f Representative flow cytometry plots for the analysis of the pAKT+ DC cells and pSTAT3+ DC cells in the CD45+ cells. Data are shown as the mean ± SD of a representative experiment, and Student’s t-test was used for the statistical test. Experiments were repeated three times with consistent results

Back to article page